Nuevocor, a Singapore-based preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, closed a $24m Series A financing round.
The round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF), with EDBI, Xora Innovation, SEEDS Capital and other investors joining the syndicate.
The company intends to use the funds to accelerate the preclinical development of its lead program, an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene and to address other untreatable cardiomyopathies using their novel target discovery platform.
Led by founding CEO Dr Yann Chong Tan, Nuevocor is a preclinical-stage biopharmaceutical company focused on developing AAV gene therapy for the treatment of genetically defined cardiac diseases with high unmet need. Its lead program, lamin A/C dilated cardiomyopathy (LMNA DCM) gene therapy is based on decades of research into fundamental mechanisms underlying LMNA-associated disease enabled by development of novel technologies on the part of scientific co-founders Colin Stewart and Brian Burke of the Agency for Science, Technology and Research (A*STAR). Together with AAV gene therapy and cardiac disease modelling expertise of scientific co-founders Mark Kay from Stanford University and Jianming Jiang from the National University of Singapore respectively, Nuevocor is positioned to treat LMNA and other genetic cardiomyopathies, amongst other cardiac diseases.